Legionella News and Research

RSS

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

ACE Environmental Advisory explores potential risks of mold and legionella at healthcare facilities

The ACE Group today announced the release of an environmental advisory entitled, "Legionella and Mold: Construction and Renovation Risks at Healthcare Facilities," which explores the potential risks of pollutants, such as mold and legionella, that hospitals and healthcare facilities can experience during renovation or construction projects.

3 Nov 2012

Positive results from Cempra's IV solithromycin Phase 1 study

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced results of its Phase 1 study of intravenous (IV) solithromycin in healthy subjects. The study demonstrated that IV solithromycin was well tolerated, showed a favorable pharmacokinetic profile (PK) and achieved relevant plasma concentrations.

8 Oct 2012

Tips to prevent illness in crowds

Massive crowds from around the globe will mingle in London during the Olympics, and that means a world-class array of germs will mix with them. Mayo Clinic infectious diseases expert Gregory Poland, M.D., offers several tips for avoiding illness when you are around lots of people, whether at the Olympics, a professional football game, convention, arena concert or other major event.

26 Jul 2012

Caspase-11 enzyme plays an important role in Legionella infection

New research shows that an enzyme that has long been considered relatively useless to the immune response instead has an important role in setting up immune cells to kill infection-causing bacteria.

13 Jun 2012

Nephros granted rights to market products based on Medica's Medisulfone ultrafiltration technology

Nephros, Inc., a medical device company developing and marketing filtration products for therapeutic applications, infection control, and advanced water purification solutions, today announced that the company has entered into a strategic license and supply agreement with Medica S.p.A.

23 Apr 2012

Data from Cempra's CEM-101 Phase 2 trial on N. gonorrhoeae infections to be presented at ECCMID

Cempra Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) demonstrating that CEM-101 (solithromycin) is active against antibiotic-resistant strains of N. gonorrhoeae.

31 Mar 2012

Data from Cempra's CEM-101 Phase 2 trial on CABP to be presented at ECCMID

Cempra Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases,today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in London, March 31 to April 3,demonstrating CEM-101's (solithromycin's) efficacy to be comparable to levofloxacin in a Phase 2 trial of patients with community-acquired bacterial infections.

31 Mar 2012

FDA clears Meridian Bioscience's TRU Legionella test

Meridian Bioscience, Inc. today announced that it has received FDA clearance from the U.S. Food and Drug Administration (FDA) for TRU Legionella, a new rapid assay for detection of legionellosis.

28 Feb 2012

Water-associated disease outbreaks more likely to occur in high population density areas

Water-associated infectious disease outbreaks are more likely to occur in areas where a region's population density is growing, according to a new global analysis of economic and environmental conditions that influence the risk for these outbreaks.

15 Feb 2012

Decorative fountain in hospital linked to 2010 Wisconsin outbreak of Legionnaires' disease

A 2010 outbreak of Legionnaires' disease in Wisconsin has been linked to a decorative fountain in a hospital lobby, according to a study published in the February issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.

11 Jan 2012

Bacteria use host proteins to build camouflaged homes inside healthy cells

Bacteria are able to build camouflaged homes for themselves inside healthy cells - and cause disease - by manipulating a natural cellular process.

21 Dec 2011

UCB initiates EXXELERATE study in rheumatoid arthritis

UCB today announced the start of the EXXELERATE study which will evaluate the short- and long-term efficacy of Cimzia (certolizumab pegol) plus methotrexate (MTX) compared with that of Humira(adalimumab) plus MTX in the treatment of moderate to severe rheumatoid arthritis (RA). The start of this study confirms previously announced plans.

21 Dec 2011

Potential new ways to design vaccines, antibiotics

A University of Louisville scientist has determined for the first time how the bacterium that causes Legionnaires' disease manipulates our cells to generate the amino acids it needs to grow and cause infection and inflammation in the lungs.

18 Nov 2011

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, is proud to sponsor several key sets of Cimzia (certolizumab pegol) data at the American College of Rheumatology's 2011 Annual Scientific Meeting in Chicago, November 5-9.

7 Nov 2011

UCB to present new data on Cimzia at ACG annual scientific meeting

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, will present new data on Cimzia at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place in Washington D.C. from October 28 to November 2.

1 Nov 2011

Legionella News and Research

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

ACE Environmental Advisory explores potential risks of mold and legionella at healthcare facilities

Positive results from Cempra's IV solithromycin Phase 1 study

Tips to prevent illness in crowds

Caspase-11 enzyme plays an important role in Legionella infection

Nephros granted rights to market products based on Medica's Medisulfone ultrafiltration technology

Data from Cempra's CEM-101 Phase 2 trial on N. gonorrhoeae infections to be presented at ECCMID

Data from Cempra's CEM-101 Phase 2 trial on CABP to be presented at ECCMID

FDA clears Meridian Bioscience's TRU Legionella test

Water-associated disease outbreaks more likely to occur in high population density areas

Decorative fountain in hospital linked to 2010 Wisconsin outbreak of Legionnaires' disease

Bacteria use host proteins to build camouflaged homes inside healthy cells

UCB initiates EXXELERATE study in rheumatoid arthritis

Potential new ways to design vaccines, antibiotics

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

UCB to present new data on Cimzia at ACG annual scientific meeting

Furiex announces publications and presentations about antibacterial drug JNJ-Q2

Biologists discover new way in which bacteria hijack healthy cells during infection

Mimicry allows bacteria to evade host's defense responses

Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting

Exploring the intersection of biology and proteomics

Unlocking the Secrets of Multiple Sclerosis Progression: Brain-Immune Cell Communication

Passing on Polycystic Ovary Syndrome: Health risks for male offspring of women with PCOS

Latest News